Fulvestrant

From Wikipedia, the free encyclopedia

Fulvestrant
Systematic (IUPAC) name
13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol
Identifiers
CAS number 129453-61-8
ATC code L02BA03
PubChem 104741
DrugBank APRD00654
Chemical data
Formula C32H47F5O3S 
Mol. mass 606.772 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 99%
Metabolism  ?
Half life 40 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

D
Legal status

Rx only
Routes Intramuscular injection

Fulvestrant, also known as ICI 182,780, and "Faslodex" is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

[edit] Clinical uses

Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

[edit] External links


[edit] References

  1. ^ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.
v • d • e
Sex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPS
Progestogens:
(receptor)
Androgens:
(receptor)
Estrogens:
(receptor)
Gonadotropins:
(FSHR/LHCGR)
GnRH:
(receptor)